Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival

European Radiology

Volumn 28, Issue 7, 2018, Pages 2727-2734

  Calandri, Marco ^a   Yamashita, Suguru ^b   Gazzera, Carlo ^a   Fonio, Paolo ^a   Veltri, Andrea ^a   Bustreo, Sara ^c   Sheth, Rahul A ^b   Yevich, Steven M ^b   Vauthey, Jean Nicolas ^b   Odisio, Bruno C ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Ablation techniques; Colorectal neoplasms; DNA mutational analysis; Interventional radiology; Metastasis

Indexed keywords

RAS PROTEIN; SULFUR HEXAFLUORIDE; DNA;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERVENTIONAL RADIOLOGY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURGICAL MARGIN; TUMOR ABLATION; TUMOR GROWTH; UNIVARIATE ANALYSIS; CLINICAL TRIAL; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; ELECTROCOAGULATION; GENETICS; LIVER TUMOR; MULTICENTER STUDY; MUTATION; ONCOGENE RAS; PATHOLOGY; PROCEDURES; REGISTER; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ELECTROCOAGULATION; FEMALE; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MARGINS OF EXCISION; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 85041495196     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-017-5273-2     Document Type: Article

References (21)

1. Shady W, Petre EN, Gonen M et al (2016) Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology 278:601–611.
2. de Baere T, Tselikas L, Yevich S et al (2017) The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer 75:231–242.
3. Solbiati L, Ahmed M, Cova L et al (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968.
4. Sofocleous CT, Petre EN, Gonen M et al (2011) CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy. J Vasc Interv Radiol 22:755–761.
5. Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 27:1386–1422.
6. Ruers T, Van Coevorden F, Punt CJA et al (2017) Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. JNCI J Natl Cancer Inst. 10.1093/jnci/djx015
7. Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213.
8. Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36:166–175.
9. Veltri A, Sacchetto P, Tosetti I et al (2008) Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival. Cardiovasc Intervent Radiol 31:948–956.
10. Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104:760–768.
11. Amado RG, Wolf M, Peeters M et al (2008) Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 26:1626–1634.
12. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 359:1757–1765.
13. Pollock CB, Shirasawa S, Sasazuki T et al (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65:1244–1250.
14. Brudvik KW, Mise Y, Chung MH et al (2016) RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 23:2635–2643.
15. Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol JVIR 25:1691–1705.e4.
16. Knijn N, Mekenkamp LJM, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020–1026.
17. Baas JM, Krens LL, Guchelaar H-J et al (2011) Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. The Oncologist 16:1239–1249.
18. Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol 25:3438–3454.
19. Pathak S, Jones R, Tang JMF et al (2011) Ablative therapies for colorectal liver metastases: a systematic review: Ablation for colorectal liver metastases. Colorectal Dis 13:e252–e265.
20. Hur H, Ko YT, Min BS et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736.
21. Aloia TA (2006) Solitary Colorectal Liver Metastasis: Resection Determines Outcome. Arch Surg 141:460.